Advertisement

Molecular Pathology of Soft Tissue and Bone Tumors

  • Neal I. Lindeman
  • Paola Dal Cin
Chapter

Abstract

This chapter presents cytogenetic and molecular pathology of sarcomas, with emphasis on recurrent abnormalities that are characteristic features of individual cancer types. General concepts concerning biology, pathology, diagnostic techniques, and molecular diagnostic applications of cancers are presented in the beginning of the chapter. The second portion presents each of the major sarcoma types, in alphabetical order, with a specific structure: basic pathology, clinical features, molecular genetic pathology, and molecular diagnosis. Most of the tumors presented herein are soft tissue sarcomas, as few recurrent abnormalities have been established to have biologic and diagnostic significance in bone tumors. In contrast to other diseases and cancers presented in this textbook, sarcomas are more commonly associated with cytogenetic changes, as opposed to molecular changes. Nevertheless, a variety of approaches (e.g., classical cytogenetic analysis, fluorescence in situ hybridization, reverse-transcriptase polymerase chain reaction, immunohistochemistry) are presented, with strengths and weaknesses of each for clinical application in each tumor type, as appropriate.

Keywords

Ewing Sarcoma Molecular Diagnostics Chromosomal Variant Endometrial Stromal Sarcoma Basic Pathology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48:13–21.PubMedCrossRefGoogle Scholar
  2. Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356–62.Google Scholar
  3. Antonescu CR, Dal Cin P, Nafa K, Teot LA, Surti U, Fletcher CD, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46:1051–60.PubMedCrossRefGoogle Scholar
  4. Antonescu CR, Zhang L, Chang N, Pawel BR, Travis W, Rosenberg AE, et al. Novel EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of 66 cases, including soft tissue, bone and visceral lesions, showing common involvement of EWSR1 gene rearrangement. Genes Chromosomes Cancer. 2010;49:1114–24.PubMedCrossRefGoogle Scholar
  5. Antonescu CR, Zhang L, Nielsen P, Rosenberg A, Dal Cin P, Fletcher CD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011;50:757–64.PubMedCrossRefGoogle Scholar
  6. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27:750–61.PubMedCrossRefGoogle Scholar
  7. Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://www.infobiogen.fr/services/chromcancer/index.html. Barr FG, Ladanyi M. Sarcomas. In: Leonard DGB, editor. Diagnostic molecular pathology. Philadelphia: Saunders; 2003, p. 53–76.
  8. Barr FG, Womer RB. Molecular diagnosis of ewing family tumors: too many fusions… ? J Mol Diagn. 2007;9:437–40.PubMedCrossRefGoogle Scholar
  9. Bovée JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch. 2010;456:193–9.PubMedCrossRefGoogle Scholar
  10. Breitfield PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. Oncologist. 2005;10:518–27.CrossRefGoogle Scholar
  11. Chang CC, Shidham VB. Molecular genetics of pediatric soft tissue tumors. J Mol Diagn. 2003;5:143–54.PubMedCrossRefGoogle Scholar
  12. Fisher C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch. 2010;456:153–66.PubMedCrossRefGoogle Scholar
  13. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040–50.PubMedCrossRefGoogle Scholar
  14. Jain S, Xu R, Prieto VG, Lee P. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol. 2010;3:416–28.PubMedGoogle Scholar
  15. Lee CH, Ou W, Marino-Enriquez A, Zhu M, Myeda M, Wang YX, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA. 2012;109:929–34.PubMedCrossRefGoogle Scholar
  16. Lemm D, Mügge LO, Mentzel T, Höffken K. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135:653–65.PubMedCrossRefGoogle Scholar
  17. Lessnick SL, Kovar H, Houghton P. The molecular basis of sarcoma. Sarcoma. 2011;2011:864130.PubMedCrossRefGoogle Scholar
  18. Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35:135–44.PubMedCrossRefGoogle Scholar
  19. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408–15.PubMedCrossRefGoogle Scholar
  20. O’Leary TJ, Frisman DM. Soft tissue and bones. In: O’Leary TJ, editor. Advanced diagnostic methods in pathology. Saunders: Philadelphia; 2003. p. 421–58.Google Scholar
  21. Ordóñez JL, Osuna D, García-Domínguez DJ, Amaral AT, Otero-Motta AP, Mackintosh C, et al. The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol. 2010;17:162–81.PubMedCrossRefGoogle Scholar
  22. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456:219–34.PubMedCrossRefGoogle Scholar
  23. Romeo S, Dei Tos AP. Clinical application of molecular pathology in sarcomas. Curr Opin Oncol. 2011;23:379–84.PubMedCrossRefGoogle Scholar
  24. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet. 2011;204:351–65.PubMedCrossRefGoogle Scholar
  25. Sorensen PHB, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2002;20:2672–9.PubMedCrossRefGoogle Scholar
  26. Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet. 2003;12:2349–58.PubMedCrossRefGoogle Scholar
  27. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ. Hogendoorn PC The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009;15(7):2259–68.PubMedCrossRefGoogle Scholar
  28. Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, et al. Recurrent (2;2) and (2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator (NCOA) family. Genes Chromosomes Cancer. 2010;49:224–36.PubMedGoogle Scholar
  29. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82.PubMedCrossRefGoogle Scholar
  30. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11(8):541–57.PubMedCrossRefGoogle Scholar
  31. Wang L, Motoi T, Khanin R, Socci N, Olshen A, Mertens F, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012;51:127–39.PubMedCrossRefGoogle Scholar
  32. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in ­rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol. 2005;23:880–8.PubMedCrossRefGoogle Scholar
  33. Xia SJ, Barr FG. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer. 2005;41:2513–27.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Neal I. Lindeman
    • 1
  • Paola Dal Cin
    • 2
  1. 1.Department of PathologyHarvard Medical SchoolBostonUSA
  2. 2.Department of PathologyThe Center for Advanced Molecular Diagnostics (CAMD), Brigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations